Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Oncology Letters|January 19, 2019
Forkhead box O1 as an indicator of prognosis is inactivated in urothelial carcinoma of the upper urinary tractHiroki Ide, Guiyang Jiang, Taichi Mizushima, et al.
Scientific Reports|October 20, 2021
Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking historyHiroki Ide, Eiji Kikuchi, Koichiro Ogihara, et al.
The Journal of Urology|January 19, 2013
Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinomaMasayuki Hagiwara, Eiji Kikuchi, Nobuyuki Tanaka, et al.
Oncotarget|June 21, 2016
Androgen receptor activity modulates responses to cisplatin treatment in bladder cancerEiji Kashiwagi, Hiroki Ide, Satoshi Inoue, et al.
American Journal of Cancer Research|November 10, 2017
Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesisTakashi Kawahara, Satoshi Inoue, Eiji Kashiwagi, et al.
British Journal of Cancer|November 15, 2017
The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cellsPeng Li, Jinbo Chen, Eiji Kashiwagi, et al.
Japanese Journal of Clinical Oncology|October 20, 2009
Docetaxel in combination with prednisolone for hormone refractory prostate cancerHiroki Ide, Eiji Kikuchi, Hidaka Kono, et al.
Molecular Endocrinology (Baltimore, Md.)|September 1, 2015
Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor TransrepressionYichun Zheng, Hitoshi Ishiguro, Hiroki Ide, et al.
Urologic Oncology|June 23, 2016
Enzalutamide inhibits androgen receptor-positive bladder cancer cell growthTakashi Kawahara, Hiroki Ide, Eiji Kashiwagi, et al.
Oncotarget|February 2, 2015
Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1Takashi Kawahara, Eiji Kashiwagi, Hiroki Ide, et al.
Pageof 8